Immunocore Quarterly Balance Sheet
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunocore financial position
As of Jun 30, 2026, Immunocore reported total assets of $1.12 billion, up 3.4% from a year earlier against total liabilities of $699.6 million. Shareholders' equity stood at $419.8 million, or 37.5% of assets. The company held $484.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.47, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Immunocore balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 484.92M | 452.68M | 467.71M | 498.41M | 487.93M | 476.85M | 455.73M | 537.77M | 504.99M | 832.82M | 442.63M | 444.14M |
| Short-Term Investments | 395.29M | 392.22M | 396.44M | 393.94M | 394.88M | 360.19M | 364.64M | 363.51M | 354.61M | — | 0 | — |
| Receivables | — | — | — | — | — | — | 63.01M | 63.66M | 60.24M | 57.75M | 52.09M | — |
| Inventory | 7.79M | 8.25M | 6.74M | 5.66M | 5.46M | 6.80M | 5.45M | 4.52M | 3.46M | 4.17M | 4.50M | — |
| Total Current Assets | 1.05B | 1.00B | 996.74M | 1.02B | 1.00B | 948.63M | 929.86M | 1.01B | 956.86M | 926.04M | 528.82M | — |
| Property, Plant & Equipment | 12.86M | 12.13M | 11.46M | 9.43M | 9.55M | 9.77M | 10.09M | 9.16M | 7.68M | 8.38M | 9.21M | — |
| Total Assets | 1.12B | 1.07B | 1.07B | 1.10B | 1.08B | 1.03B | 1.01B | 1.08B | 1.02B | 993.99M | 597.00M | — |
| Accounts Payable | 26.32M | 30.16M | 24.36M | 22.96M | 23.86M | 29.11M | 25.10M | 19.72M | 19.95M | 15.50M | 17.80M | — |
| Total Current Liabilities | 235.20M | 240.11M | 246.70M | 170.35M | 170.08M | 149.16M | 212.18M | 266.25M | 185.10M | 155.29M | 139.02M | — |
| Long-Term Debt | — | — | — | — | — | — | — | 438.69M | 452.50M | 452.50M | — | — |
| Total Liabilities | 699.62M | 678.42M | 686.24M | 705.94M | 693.91M | 649.53M | 648.79M | 706.81M | 664.23M | 634.45M | 228.16M | — |
| Shareholders' Equity | 419.80M | 393.67M | 381.03M | 396.56M | 388.48M | 378.48M | 360.72M | 377.83M | 359.14M | 359.53M | 368.84M | 355.97M |
| Retained Earnings | -819.11M | -818.30M | -831.27M | -801.22M | -801.04M | -790.74M | -795.76M | -771.99M | -780.73M | -769.11M | -744.67M | — |
| Total Debt | — | — | — | — | — | — | — | 438.69M | 452.50M | 452.50M | — | — |
| Net Cash (Debt) | 880.21M | 844.90M | 864.15M | 892.35M | 882.81M | 837.03M | 820.38M | 462.59M | 407.10M | 380.32M | 442.63M | 444.14M |
| Shares Outstanding | 51.48M | 50.83M | 50.69M | 50.47M | 50.37M | 50.18M | 50.06M | 50.03M | 50.02M | 50.01M | 49.73M | — |
This table shows 12 quarterly periods of Immunocore's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IMCR's reporting calendar. What is a balance sheet?